BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:M8 Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies M8 Pharmaceuticals's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02736656-10826@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Qelbree (viloxazine): Phase 3 readout est. (NCT02736656)
DESCRIPTION:Qelbree (viloxazine)\, phase 3\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: Open-label Study to Evaluate Long-term Safety and Effi
 cacy of SPN-812 (Viloxazine Extended-release Capsule)\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/viloxazine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02736656
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
